We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 5

1.
Figure 4

Figure 4. From: Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.

 Cumulative probability of survival was 72+13% at 5 years according to Kaplan-Meier plot calculation.

D Farge, et al. Ann Rheum Dis. 2004 August;63(8):974-981.
2.
Figure 3

Figure 3. From: Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.

 Evaluation of TLCO in patients with severe SSc before inclusion (n = 47) and then at 6 (n = 25), 12 (n = 26), 24 (n = 18), and 36 (n = 10) months after HSCT. The proportional change from baseline measurement was calculated for each patient at each available point using the Wilcoxon signed rank test (NS).

D Farge, et al. Ann Rheum Dis. 2004 August;63(8):974-981.
3.
Figure 1

Figure 1. From: Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.

 Evaluation of skin score in patients with severe systemic sclerosis before inclusion (n = 47) and then at 6 (n = 37), 12 (n = 30), 24 (n = 19), and 36 (n = 10) months after HSCT. The proportional change from baseline measurement was calculated for each patient at each available point using the Wilcoxon signed rank test, (p<0.001).

D Farge, et al. Ann Rheum Dis. 2004 August;63(8):974-981.
4.
Figure 5

Figure 5. From: Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.

 Cumulative probability of disease progression in 57 patients with severe SSc, as reported by local investigators, was estimated at 48+20% at 5 years according to the Kaplan-Meier method calculation. Disease progression was defined by an increase in skin score >25% compared with baseline values, the onset of a decrease in VC or in TLCO >15% compared with baseline, and/or progressive vital organ failure.

D Farge, et al. Ann Rheum Dis. 2004 August;63(8):974-981.
5.
Figure 2

Figure 2. From: Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.

 Evaluation of vital capacity (VC) in patients with severe systemic sclerosis before inclusion (n = 47) and then at 6 (n = 26), 12 (n = 27), 24 (n = 18), and 36 (n = 10) months after HSCT. There was no significant deterioration for each patient when calculated at the available point compared with the baseline measurement using the Wilcoxon signed rank test (NS).

D Farge, et al. Ann Rheum Dis. 2004 August;63(8):974-981.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk